KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

METHERGIN 0.125 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

0.125 MG

 

GENERIC NAME:

METHYLERGONOVINE MALEATE

 

MANUFACTURER:

NOVARTIS PHARMA

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Obstetrics, adjunct

 

SIDE EFFECTS:

Bradycardia

coronary vasospasm

Allergic reaction, including shock

cardiac arrest or ventricular arrhythmias, including fibrillation and tachycardia

dyspnea

hypertension, sudden and severe

myocardial infarction

peripheral vasospasm

Nausea

uterine cramping

vomiting

Abdominal or stomach pain

diarrhea

dizziness

sweating

tinnitus

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Allergy or sensitivity to methylergonovine or other ergot alkaloids

>> Hepatic function impairment

Hypocalcemia

>> Mitral valve stenosis

>> Venoatrial shunts

>> Renal function impairment

>> Sepsis

 

ADULT DOSE:

Uterine stimulant- Oral, 200 to 400 mcg (0.2 to 0.4 mg) two to four times a day (every six to twelve hours) until the danger of uterine atony and hemorrhage has passed. Note: Generally, a treatment course of 48 hours is sufficient . However, in some patients, treatment for up to 7 days may be necessary, especially when used for treatment of incomplete abortion . Oral administration usually follows an initial parenteral dose.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT